Navigation Links
Potential Acquisitions and Stock Price Updates - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics
Date:11/26/2013

NEW YORK, November 26, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Covidien plc (NYSE: COV), United Therapeutics Corporation (NASDAQ: UTHR), Brookdale Senior Living Inc. (NYSE: BKD) and Seattle Genetics Inc. (NASDAQ: SGEN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

BioMarin Pharmaceutical Inc. Research Report

On November 22, 2013, Bloomberg reported that BioMarin Pharmaceutical Inc. (BioMarin) is likely to emerge as a prospective acquisition candidate after an advisory committee to the Food and Drug Administration, voted in favor of approval for Vimizim, the Company's most promising rare-disease drug. Kimberly Lee, a San Francisco-based Managing Director and Analyst at a financial services firm Janney, commented via a phone interview with Bloomberg, "It's a good acquisition candidate given big pharma's interest in the orphan drug development space and given BioMarin's deep pipeline." According to the Bloomberg report, Phil Nadeau, a New York-based Analyst at Cowen Group Inc., said via a phone interview, "Large drugmakers do want good products and growing products, and with Vimizim now very likely to get to the market, that's another one of those in BioMarin's portfolio. BioMarin is a good candidate and probably a likely candidate at this point to be acquired." The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/9b6c_BMRN

--

Covidien plc Research Report  

On November 21, 2013, Covidien plc's (Covidien) stock increased 0.47%, ending the day's trading session at $66.68. Over the previous three trading sessions, shares of Covidien increased 0.24%, compared to the Dow Jones Industrial Average Index, which increased 0.21% during the same period. The Full Research Report on Covidien plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/a14c_COV

--

United Therapeutics Corporation Research Report  

On November 21, 2013, United Therapeutics Corporation's (United Therapeutics) stock increased 1.05%, ending the day's trading session at $92.60. Over the previous three trading sessions, shares of United Therapeutics increased 1.35%, compared to the Nasdaq Composite Index, which increased 0.51% during the same period. The Full Research Report on United Therapeutics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/e4cc_UTHR

--

Brookdale Senior Living Inc. Research Report

On November 21, 2013, Brookdale Senior Living Inc.'s (Brookdale) stock increased 0.97%, ending the day's trading session at $29.00. Over the previous three trading sessions, shares of Brookdale declined 1.36%, compared to the Dow Jones Industrial Average Index, which increased 0.21% during the same period. The Full Research Report on Brookdale Senior Living Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/fefe_BKD

--

Seattle Genetics Inc. Research Report

On November 21, 2013, Seattle Genetics Inc.'s (Seattle Genetics) stock increased 0.30%, ending the day's trading session at $40.50. Over the previous three trading sessions, shares of Seattle Genetics declined 1.72%, compared to the Nasdaq Composite Index, which increased 0.51% during the same period. The Full Research Report on Seattle Genetics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/ff98_SGEN

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AnalystsCorner.com

 


'/>"/>
SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Primer Co-Authored by Novation Describes Potential Impact of Biosimilars on Pharmacy Practice; Opportunity for Hospitals to Manage Drug Expenditures
2. How to Maximize the Potential of New Medical Device Products While Protecting the Impact on Legacy Brands in the Same Therapeutic Area
3. Perrigo Initiates Nationwide Voluntary Product Recall Of Acetaminophen Infant Suspension Liquid, 160 mg/5 mL, Due To A Potential Defect With The Co-Packaged Oral Syringe
4. New Findings Published In Circulation: Heart Failure Show Potential Utility Of Cardioxyls HNO Donors As Novel Treatments For Heart Failure
5. Pain Management Modifier: Inappropriate Use of Modifiers Can Put You at Risk for Potential Fines
6. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
7. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
8. IceCure Enters a New High-Potential Market: The company received $100K-order for cryoablation consoles and probes to be used in a clinical study for the treatment of lung cancer
9. Transformed Interoperable Smart Pumps Improve Patient Compliance and Market Potential
10. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
11. Revolutionary Natural Sunscreen That Can Reverse Wrinkles, Fine Lines, Sagging Skin, Laugh Lines And Potentially Reverse Cancer Cell Formation With Anti-Aging And Anti-Cancer Forming Natural Ingredients Now Available From Rejuve MD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... New York , February 20, 2017 ... regularized absorption of calcium and phosphorous minerals in one,s ... of vitamin D ingredients in maintaining a healthy composition ... medicines containing vitamin D ingredients is growing in the ... advantage of consuming vitamin D ingredients for treatment of ...
(Date:2/19/2017)... 19, 2017  nThrive™, an independent Patient-to-Payment? solutions ... thought leadership at the 2017 HIMSS Conference. The ... award from KLAS. nThrive will host ... how market trends shape the holistic, integrated revenue ... comprehensive Patient Access solution. The panel will reveal ...
(Date:2/18/2017)... PORT WASHINGTON, N.Y. , Feb. 17, 2017 ... law firm dedicated to protecting the rights of ... device problems have prompted regulators to call for ... events in 1990. Safety concerns involving ... and Drug Administration (FDA) to investigate how hospitals ...
Breaking Medicine Technology:
(Date:2/20/2017)... , ... February 20, 2017 , ... Researchers at the ... cancer, as well as a marker that may predict response to a particular class ... other types of cancer as well. The new findings were published in Proceedings of ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... announced Biscom Document Router (BDR), the first IoT device from Biscom designed to ... imaging. Biscom will debut BDR at HIMSS17 and will be conducting ...
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ReportingMD, a Population Health Software Company, is ... of the company. The new location will triple the size of the previous location ... the town of Sunapee, NH. , “We are excited to expand our footprint ...
(Date:2/20/2017)... ... ... Chuck E. Cheese’s® and Center for Autism and Related Disorders (CARD) recently announced ... throughout New England, New York and New Jersey to provide children with autism spectrum ... Chuck E. Cheese’s in a sensory-friendly environment. , After a successful pilot run ...
(Date:2/19/2017)... Carolina (PRWEB) , ... February 19, 2017 , ... The ... evening undergraduate nursing students, is being led by Amelia Joseph, Ph.D. Joseph was engaged ... initial operations of the nursing department in early 2016. After a nation-wide search, she ...
Breaking Medicine News(10 mins):